APD-356 (Arena).

Ronald J, Jandacek

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2006

Data sources: Europe PubMed Central

APD-356 (Arena).

descriptionPublicationkeyboard_double_arrow_right Article 06 Jan 2006 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 6 (issn: 1472-4472,

Copyright policy )

Authors: Ronald J, Jandacek;

pmid: 16259227

APD-356 (Arena).

- Summary
- Subjects
- Metrics

Abstract

Arena is developing APD-356, the lead in a series of orally active, small-molecule 5-hydroxytryptamine 2C agonists for the potential treatment of obesity and diabetes. A phase IIb trial was initiated in June 2005, and preliminary results were expected at the end of 2005.

Related Organizations

University System of Ohio
United States
University of Cincinnati
United States

Keywords

Clinical Trials as Topic, Drug Industry, Benzazepines, Structure-Activity Relationship, Treatment Outcome, Appetite Depressants, Diabetes Mellitus, Animals, Humans, Hypoglycemic Agents, Obesity, Serotonin 5-HT2 Receptor Agonists

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average